Drug Sales Trends for DEPAKOTE

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for DEPAKOTE

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
DEPAKOTE			2022
DEPAKOTE			2021
DEPAKOTE			2020
DEPAKOTE			2019
DEPAKOTE			2018
DEPAKOTE			2017
DEPAKOTE			2016

Last updated: September 3, 2026

ecutive summary: Depakote is a mature, largely genericized divalproex sodium franchise with limited remaining patent protection and declining branded commercial relevance. AbbVie does not separately disclose current Depakote revenue in a way that supports a precise brand-only forecast. A market-based model indicates U.S. branded Depakote revenue of approximately $250 million to $320 million in 2025, declining to $150 million to $220 million by 2029 under a base case. The broader divalproex market should remain materially larger, supported by chronic epilepsy treatment, bipolar disorder maintenance, and use in institutional and specialty settings.

Depakote Market Analysis and Sales Projections Through 2029

What is Depakote and which products are included in the franchise?

Depakote is the brand name for divalproex sodium, a valproate product marketed primarily by AbbVie. Divalproex sodium dissociates to valproate in the gastrointestinal tract and is used in epilepsy, acute manic or mixed episodes associated with bipolar disorder, and migraine prophylaxis.

The franchise includes several dosage forms:

Product	Active ingredient	Primary use	Commercial status
Depakote delayed-release tablets	Divalproex sodium	Epilepsy, bipolar mania, migraine prevention	Generic competition
Depakote ER extended-release tablets	Divalproex sodium	Epilepsy, bipolar mania	Generic competition
Depakote Sprinkle Capsules	Divalproex sodium	Epilepsy, primarily patients needing administration flexibility	Generic competition
Depacon injection	Valproate sodium	Intravenous seizure treatment when oral therapy is impractical	Generic competition
Depakene	Valproic acid	Epilepsy and related valproate therapy	Separate but overlapping franchise

The commercial analysis should distinguish branded Depakote revenue from the total divalproex market. Most prescriptions are now filled with generic divalproex sodium rather than AbbVie’s branded products.

How large is the Depakote and divalproex market?

The total divalproex market remains clinically significant but is mature and price-sensitive. Demand is driven by the number of patients requiring long-term antiseizure therapy and by continued use in bipolar disorder. Migraine prevention contributes less volume than epilepsy and psychiatric indications.

Estimated U.S. market structure

Segment	2025 estimated U.S. sales	Growth outlook through 2029	Main driver
Branded Depakote and related AbbVie products	$250 million-$320 million	-5% to -8% annually	Residual brand loyalty and institutional demand
Generic divalproex sodium	$450 million-$650 million	0% to 3% annually	Chronic prescription volume
Total oral divalproex market	$700 million-$950 million	Flat to low single-digit growth	Stable treatment population
Injectable valproate market	$100 million-$180 million	1% to 4% annually	Hospital and acute-care use
Global divalproex and valproate market	$1.4 billion-$2.0 billion	1% to 3% annually	Emerging-market volume and persistent clinical use

These figures are analytical estimates rather than reported AbbVie guidance. They reflect the loss of exclusivity, generic substitution, mature prescription demand, and limited innovation in the product class.

The total valproate market is broader than Depakote because it includes divalproex sodium, valproic acid, valproate sodium, generic products, and non-U.S. brands.

What were Depakote’s historical sales?

Depakote was a major Abbott pharmaceutical product before AbbVie separated from Abbott in 2013. Reported sales declined as generic competition expanded and patent protection ended.

Year	Reported Depakote sales	Company	Source context
2014	Approximately $927 million	AbbVie	Annual report product sales
2015	Approximately $731 million	AbbVie	Annual report product sales
2016	Approximately $569 million	AbbVie	Annual report product sales
2017 onward	Not consistently disclosed as a standalone current franchise metric	AbbVie	Reduced reporting prominence

The decline from 2014 through 2016 represents a compound annual decrease of approximately 22%. The principal causes were generic substitution, erosion of branded pricing power, and reduced contribution from legacy formulations.

AbbVie’s current revenue reporting is concentrated on larger growth products, including immunology, oncology, neuroscience, aesthetics, and migraine products. Depakote is no longer a core disclosed growth asset.

What are the Depakote sales projections for 2025 through 2029?

The base-case forecast assumes continued generic substitution, stable clinical demand, modest price erosion, and no major withdrawal from the market.

U.S. branded Depakote revenue forecast

Year	Bear case	Base case	Bull case
2025	$230 million	$285 million	$325 million
2026	$210 million	$265 million	$315 million
2027	$190 million	$245 million	$305 million
2028	$170 million	$225 million	$295 million
2029	$150 million	$205 million	$285 million

Scenario assumptions

The bear case assumes faster conversion to generic divalproex, continued payer pressure, reduced physician preference for branded products, and lower institutional purchasing.

The base case assumes a 7% annual decline in branded revenue. This reflects the behavior of mature off-patent products that retain some demand from physicians, patients, hospitals, and pharmacies but have limited pricing leverage.

The bull case assumes slower brand erosion caused by supply disruptions among generic manufacturers, persistent demand for specific dosage forms, and stable institutional contracts. It does not assume a return to exclusivity or material price increases.

Total U.S. divalproex market forecast

Year	Estimated total U.S. market
2025	$700 million-$950 million
2026	$710 million-$970 million
2027	$720 million-$990 million
2028	$730 million-$1.01 billion
2029	$740 million-$1.03 billion

The total market can remain stable while branded Depakote declines because generic manufacturers capture a larger share of prescriptions and maintain lower prices.

When did Depakote lose exclusivity?

Depakote has lost the exclusivity characteristics associated with a protected innovative product. The key formulations have faced generic competition for many years, and the original compound, delayed-release, extended-release, and sprinkle products do not provide a credible basis for a new period of market exclusivity.

Protection category	Commercial implication
Original valproate and divalproex patents	Expired or commercially exhausted
Delayed-release tablet protection	Generic competition established
Extended-release formulation protection	Generic competition established
Sprinkle capsule protection	Generic competition established
Orphan-drug exclusivity	No current exclusivity relevant to ordinary Depakote sales
Pediatric exclusivity	Historical, not commercially blocking today
Data exclusivity	Expired
Regulatory exclusivity	No current blocking period identified

A generic applicant does not need to overcome a meaningful remaining Depakote patent barrier for ordinary entry. Market access is primarily a regulatory, manufacturing, supply, and commercial execution issue.

What is the FDA regulatory status of Depakote?

Depakote is FDA-approved for:

• Complex partial seizures, either alone or with other seizure types.
• Absence seizures, alone or with other seizure types.
• Manic episodes associated with bipolar disorder.
• Prevention of migraine headaches.

Depakote is not approved for acute treatment of migraine pain. Its migraine indication is preventive.

Valproate products carry major safety restrictions. The FDA labeling includes boxed warnings for hepatotoxicity, fetal risk, and pancreatitis. Valproate exposure during pregnancy is associated with neural tube defects and other adverse developmental outcomes. These risks affect prescribing, patient counseling, reproductive-health restrictions, and long-term market demand.

The safety profile can favor competing antiseizure or migraine-prevention products when clinical alternatives are suitable. It also limits use in women of childbearing potential and creates additional monitoring requirements.

What patents protect Depakote and are any Orange Book barriers remaining?

The commercial patent estate is weak because the main product patents and formulation protections have already been exposed to generic competition. The Orange Book historically included patents associated with Depakote formulations and related products, but those listings do not create a current, durable barrier comparable to a newly launched branded medicine.

The relevant intellectual-property categories were:

1. Divalproex sodium composition and pharmaceutical forms.
2. Enteric-coated delayed-release tablets.
3. Extended-release dosage forms.
4. Sprinkle capsules.
5. Manufacturing and formulation processes.
6. Labeling and method-of-use claims.

Method-of-use patents have limited practical value when the approved indications are longstanding, generic labels are available, and prescribing can occur under established clinical practice. Formulation patents also have reduced value when multiple generic dosage forms have been approved.

No current Paragraph IV challenge is commercially central to the Depakote franchise. The important generic litigation cycle occurred during the earlier loss-of-exclusivity period. Current competition is better analyzed through generic approvals, pricing, supply reliability, and channel share than through pending patent litigation.

Which companies compete with Depakote?

Competition occurs at both the molecule level and the therapeutic-class level.

Generic divalproex competitors

Generic competition includes manufacturers of delayed-release tablets, extended-release tablets, and sprinkle capsules. The specific supplier mix changes over time because generic manufacturers enter, exit, consolidate, or experience manufacturing disruptions.

Generic products compete primarily on:

• Wholesale acquisition cost.
• Pharmacy benefit manager formulary position.
• Supply reliability.
• Dosage-form availability.
• Product quality and regulatory compliance.
• Hospital and institutional contracts.

Therapeutic alternatives

Therapy	Main competitive area	Relative commercial effect
Levetiracetam	Epilepsy	Strong substitution option with broad use
Lamotrigine	Epilepsy and bipolar maintenance	Important alternative, especially in selected psychiatric patients
Topiramate	Epilepsy and migraine prevention	Competes in both major non-psychiatric uses
Carbamazepine	Epilepsy and bipolar disorder	Older alternative with drug-interaction limitations
Lithium	Bipolar disorder	Competes mainly in mood stabilization
Atypical antipsychotics	Bipolar mania and maintenance	Major competition in psychiatric treatment
CGRP-targeted therapies	Migraine prevention	Reduces valproate use in eligible migraine patients

Levetiracetam and lamotrigine are the most important epilepsy alternatives in many prescribing settings. In bipolar disorder, lithium and atypical antipsychotics compete more directly than newer antiseizure drugs. In migraine, CGRP monoclonal antibodies and oral CGRP antagonists have expanded treatment choices, although their higher cost can preserve a role for generic valproate.

What generic entry risks affect Depakote sales?

The principal risk is continued branded-to-generic conversion rather than a single future launch event.

High-probability risks

• Further pharmacy substitution for Depakote delayed-release tablets.
• Reduced reimbursement for branded extended-release products.
• Payer-mandated step therapy involving generic antiseizure drugs.
• Generic entry or re-entry in under-supplied dosage forms.
• Hospital purchasing based on lowest-cost injectable valproate.
• Physician migration toward levetiracetam, lamotrigine, or newer migraine agents.
• Lower use in women of reproductive potential because of fetal-risk concerns.

Offsetting factors

• Long-established clinical familiarity.
• Availability of multiple dosage forms.
• Low generic cost and broad reimbursement.
• Continued need for seizure control in chronic patients.
• Use in patients who are stable on existing therapy.
• Institutional demand for oral and intravenous valproate.

How strong is the Depakote patent estate?

The estate is weak from a new-product investment perspective but still has residual defensive value around manufacturing, trademarks, regulatory know-how, and selected formulation claims.

Factor	Assessment
Remaining exclusivity	Low
Generic blocking power	Low
Formulation differentiation	Low to moderate
Manufacturing complexity	Low to moderate
Regulatory switching friction	Moderate
Trademark value	Moderate in legacy channels
Pricing power	Low
Litigation leverage	Low
Long-term growth potential	Low

Divalproex is not a biologic and has no biosimilar risk. Its competitive exposure is conventional generic substitution. Manufacturing barriers are also limited relative to complex injectables, long-acting products, or biologics, although quality controls and supply continuity remain operational concerns.

What is the commercial outlook for Depakote?

Depakote is likely to remain a cash-generating but declining legacy franchise. Its value is based on residual volume, not innovation or patent exclusivity.

The most probable commercial path is:

1. Branded revenue continues to decline at a mid-single-digit to high-single-digit rate.
2. Generic divalproex captures most prescription growth.
3. Total molecule demand remains broadly stable.
4. Newer epilepsy, bipolar, and migraine products take selected patients.
5. Safety restrictions limit expansion in reproductive-age populations.
6. Product-specific supply reliability determines short-term share changes.
7. AbbVie’s strategic focus remains outside Depakote.

A buyer or licensee would need to value Depakote as a mature cash-flow asset with limited upside. The principal diligence priorities would be net pricing, channel mix, generic substitution, manufacturing costs, product liability exposure, regulatory compliance, and the remaining customer base.

Key takeaways

• Depakote is a mature divalproex sodium franchise with extensive generic competition.
• Estimated U.S. branded revenue is approximately $250 million to $320 million in 2025.
• Base-case branded revenue declines to approximately $205 million by 2029.
• The broader U.S. divalproex market is estimated at $700 million to $950 million in 2025 and should remain broadly stable.
• Depakote has no meaningful current patent or regulatory exclusivity supporting a new generic-entry barrier.
• Generic divalproex, levetiracetam, lamotrigine, lithium, atypical antipsychotics, and newer migraine therapies are the principal competitive threats.
• The main commercial risk is continued generic substitution, not Paragraph IV litigation.
• Safety restrictions, particularly fetal-risk warnings, constrain prescribing and future growth.

FAQs about Depakote market size, patents, and future sales

Is Depakote still profitable for AbbVie?

Depakote can remain profitable because manufacturing and commercial costs are lower for a mature product, but it is no longer a principal AbbVie growth driver. Current standalone brand profitability is not publicly disclosed.

Will generic Depakote reduce the price of divalproex sodium?

Yes. Generic substitution places sustained pressure on branded pricing and typically shifts prescription volume toward lower-cost manufacturers. The effect is strongest where pharmacy benefit managers impose mandatory substitution.

Can Depakote sales grow through new indications?

Meaningful indication-driven growth is unlikely without new clinical evidence, label expansion, or a reformulated product with differentiated safety or adherence benefits. The core indications are longstanding.

Does Depakote face biosimilar competition?

No. Depakote is a small-molecule drug, not a biologic. Its competitive risk comes from traditional generic manufacturers.

Is Depakote a takeover or licensing target?

It is more likely to attract buyers seeking mature branded cash flow, established distribution, or selected dosage-form rights than buyers seeking a high-growth pharmaceutical asset. Valuation would depend heavily on remaining net sales, liability reserves, manufacturing economics, and generic share.

References

1. AbbVie Inc. (2015). 2014 annual report. AbbVie Inc.

2. AbbVie Inc. (2016). 2015 annual report. AbbVie Inc.

3. AbbVie Inc. (2017). 2016 annual report. AbbVie Inc.

4. U.S. Food and Drug Administration. (2024). Depakote prescribing information. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2024). Valproate information. U.S. Department of Health and Human Services.

7. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. U.S. Department of Health and Human Services.